SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verrica Pharmaceuticals, Inc. - VRCA

NEW YORK, July 09, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Verrica Pharmaceuticals, Inc. (""Verrica or the "Company") (NASDAQ: VRCA).   Such investors are advised to contact Robert S. Willoughby at  newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether Verrica and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] In December 2020, Verrica submitted its New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") seeking regulatory approval of VP-102 for the treatment of molluscum.  Then, on September ... Full story available on Benzinga.com